| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Tenax Therapeutics Inc. | Levosimendan | Septic shock | Phase 2b | Trial Discontinued | Intravenous | N/A |
| Terns Pharmaceuticals Inc. | TERN-601 - (FALCON) | Obesity | Phase 2 | Trial Discontinued | oral | Endocrinology |
| Terns Pharmaceuticals Inc. | TERN-501 - (DUET) | Nonalcoholic steatohepatitis (NASH) | Phase 2a | Data Released | Oral | Gastroenterology |
| Terns Pharmaceuticals Inc. | TERN-101 - (LIFT) | Nonalcoholic steatohepatitis (NASH) | Phase 2a | Ongoing | Oral | Gastroenterology |
| Teva Pharmaceutical Industries Limited American Depositary Shares | AVT06 - (EYLEA biosimilar) | Eye disorders | BLA Filing | Data Released | Intravitreal injection | Opthalmic |
| Teva Pharmaceutical Industries Limited American Depositary Shares | Olanzapine LAI (44749) - (SOLARIS) | Schizophrenia | NDA Filing | Ongoing | Intramuscular | Psychiatric |
| Teva Pharmaceutical Industries Limited American Depositary Shares | Fasinumab | Osteoarthritis pain of the hip or knee | Phase 3 | Trial Discontinued | Intravenous | Orthopedic |
| Teva Pharmaceutical Industries Limited American Depositary Shares | Fasinumab | Osteoarthritis pain of the hip or knee | Phase 3 | Trial Discontinued | Intravenous | Orthopedic |